Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 SPd versus EloPd in relapsed or refractory multiple myeloma
2021-001691-41Phase 3Active
- Sponsor
- European Myeloma Network
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of selinexor in multiple myeloma (MM) (2 arms), sponsored by European Myeloma Network. Primary endpoint: Progression-free survival. Started Oct 2021; status: active.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2021-001691-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001691-41.